Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders

NCT01392989 is registered in ClinicalTrials.gov with Everett Meyer as lead sponsor.

NCT NCT01392989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01392989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders
Lead sponsor
Everett Meyer
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
March 19, 2017
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, bone marrow transplant failure, leukemia, myeloid, myelodysplastic syndromes (mds), myeloproliferative disorders, neural tube defects